# Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines

> **NCT04875676** · PHASE1,PHASE2 · COMPLETED · sponsor: **Vaxart** · enrollment: 30 (actual)

## Conditions studied

- Norovirus Infections

## Interventions

- **BIOLOGICAL:** VXA-G1.1-NN

## Key facts

- **NCT ID:** NCT04875676
- **Lead sponsor:** Vaxart
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-04-30
- **Primary completion:** 2021-10-30
- **Final completion:** 2022-02-16
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04875676

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04875676, "Immunogenicity & Safety Study of Adenovirus Type 5 (AD5) Based Oral Norovirus Vaccines". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT04875676. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*